To the Editor:

Autologous bone marrow (BM) and peripheral blood (PB) stem cell transplantation (SCT) is widely used in a variety of hematological malignancies and solid tumors.1 After high-dose conditioning therapy,2 the recovery of hematopoiesis is dependent on stem cell self-renewal and differentiation into lineage-committed progenitors, which undergo differentiation and maturation to morphologically recognizable precursors and terminal cells circulating in PB.

SCT is associated with absolute leukopenia before hematopoietic recovery.2 Administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF ) and G-CSF accelerates hematopoietic recovery.3 A number of investigators have detected elevated plasma G-CSF,4-9 GM-CSF,4 interleukin-3 (IL-3),10 M-CSF,7,11 IL-6,4,5,11 and IL-8 following myeloablation and marrow or PB progenitor cell transplantation. Time-course studies have demonstrated kinetic profiles that imply a relationship between cytokine levels and engraftment. In this context, we have previously shown that (1) G-CSF, IL-8, and IL-6 levels peak at the time of neutrophil nadir8,9; (2) G-CSF, IL-8, and IL-6 peak levels directly correlate with maximum neutrophil counts. Hence, it was proposed that these three cytokines are coordinately secreted after SCT and mediate the production and activation of neutrophils.8,9 Finally, recent studies11,12 have provided evidence that accessory cells do not contribute to the production of endogenous cytokines released after SCT; in fact, patients transplanted with purified CD34+ cells release cytokines, including G-CSF, IL-6, IL-8, and IL-3, at levels similar to those observed in patients transplanted with total PBMCs.11 12 

Table 1.

Ovarian Cancer Patients: Main Cliical Features, Infused Cells, and PBMC Recovery

Patient No.AgeInfused PBMCsPBMC Recovery
MNCCFU-GM (× 104/kg)WBCPMNCPlatelets >50 × 109/L days
(× 108/kg)>1 × 109/L days>0.5 × 109/L days
35 11.7 40.3 10 10 11 
36 7.3 59.2 11 12 10 
38 13.0 67.2 10 10 
35 9.2 19.4 10 10 12 
47 8.9 19.2 11 11 11 
44 5.8 46.1 11 11 11 
43 7.8 130.1 11 
57 6.1 36.0 10 
47 7.9 51.9 
10 54 6.9 18.6 11 
11 36 7.7 22.3 10 10 14 
12 46 8.4 35.5 10 10 10 
13 54 5.4 12.5 13 
14 44 4.5 44.0 10 
15 44 7.0 46.2 12 
16 56 1.7 33.2 11 
17 40 6.7 45.1 10 
18 55 5.0 N.V. 10 10 11 
19 51 3.3 11.9 13 
20 60 5.8 N.V. 10 12 
21 57 5.1 N.V. 10 
       
Patients 1 to 6 PBSCT Patients 7 to 15 PBSCT + G-CSF/Epo Patients 16 to 21 PBSCT + G-CSF/Epo 
       
Patient No.AgeInfused PBMCsPBMC Recovery
MNCCFU-GM (× 104/kg)WBCPMNCPlatelets >50 × 109/L days
(× 108/kg)>1 × 109/L days>0.5 × 109/L days
35 11.7 40.3 10 10 11 
36 7.3 59.2 11 12 10 
38 13.0 67.2 10 10 
35 9.2 19.4 10 10 12 
47 8.9 19.2 11 11 11 
44 5.8 46.1 11 11 11 
43 7.8 130.1 11 
57 6.1 36.0 10 
47 7.9 51.9 
10 54 6.9 18.6 11 
11 36 7.7 22.3 10 10 14 
12 46 8.4 35.5 10 10 10 
13 54 5.4 12.5 13 
14 44 4.5 44.0 10 
15 44 7.0 46.2 12 
16 56 1.7 33.2 11 
17 40 6.7 45.1 10 
18 55 5.0 N.V. 10 10 11 
19 51 3.3 11.9 13 
20 60 5.8 N.V. 10 12 
21 57 5.1 N.V. 10 
       
Patients 1 to 6 PBSCT Patients 7 to 15 PBSCT + G-CSF/Epo Patients 16 to 21 PBSCT + G-CSF/Epo 
       

In the present study, the PBSCT model has been analyzed to investigate (1) the influence of exogenous G-CSF/erythropoietin (Epo) and GM-CSF/Epo on the production of IL-3, GM-CSF, G-CSF, M-CSF, IL-8, and IL-6; (2) the relationship between IL-5 release and eosinophil response, and the effect of exogenous GM-CSF and G-CSF on these parameters; and (3) the relationship of lactoferrin (Lf) plasma levels with the initial G-CSF peak and the subsequent neutrophil rescue. Modifications of plasma cytokine levels may be due to changes in production, release, consumption, or clearance. This clinical approach allows to establish temporal correlations between hematopoietic growth factor (HGF) administration and fluctuations of endogenous serum cytokines. However, the underlying cause/effect mechanisms remain largely hypothetical. Furthermore, because exogenous GM-CSF or G-CSF was combined with Epo, the specific role of each cytokine cannot be determined. Despite these limitations intrinsic to the clinical setting, the results provide novel information on the interaction between exogenous HGFs and the SCT-related cytokine release network.

We have also monitored the plasma concentrations of HGFs (ie, IL-3, GM-CSF, G-CSF, Epo, IL-8, IL-6, and IL-5) and granule proteins (Lf and myeloperoxidase [Mpo]) in 21 ovarian cancer patients undergoing autologous PB SCT (Table 1).

G-CSF levels were markedly higher after exogenous G-CSF/Epo, as expected; furthermore, they were significantly lower following GM-CSF/Epo than after SCT alone; GM-CSF levels, moderately elevated after exogenous GM-CSF/Epo, were similar in the G-CSF/Epo and control groups. Finally, patients treated with either G-CSF/Epo or GM-CSF/Epo showed higher Epo plasma concentrations than the group receiving no exogenous HGFs (Fig 1 and data not shown).

Fig. 1.

Neutrophil, monocyte, and eosinophil recovery, and G-CSF, Epo, IL-6, IL-8, and IL-5 plasma levels in 21 ovarian cancer patients (6 treated with no exogenous HGFs, 9 with G-CSF/Epo, and 6 with GM-CSF/Epo) undergoing SCT after high-dose chemotherapy. Chemotherapy days were −5 to −3 and SCT was performed on day 0. Mean ± SEM values are presented.

Fig. 1.

Neutrophil, monocyte, and eosinophil recovery, and G-CSF, Epo, IL-6, IL-8, and IL-5 plasma levels in 21 ovarian cancer patients (6 treated with no exogenous HGFs, 9 with G-CSF/Epo, and 6 with GM-CSF/Epo) undergoing SCT after high-dose chemotherapy. Chemotherapy days were −5 to −3 and SCT was performed on day 0. Mean ± SEM values are presented.

Close modal

When compared with SCT alone, (1) G-CSF/Epo treatment moderately increased the IL-3 level peaking at day +10, and did not significantly modify M-CSF level (data not shown), whereas it almost completely suppressed IL-8 and moderately decreased IL-6 and IL-5 levels (Fig 1); (2) GM-CSF/Epo treatment increased M-CSF, associated with a moderate increase of IL-3 levels peaking at day +10, moderately decreased both IL-5 and IL-8 concentration and did not modify IL-6 (Fig 1 and data not shown).

These observations indicate that exogenous G-CSF treatment induces a marked decrease of IL-8 levels and moderately decreased IL-6 concentrations, whereas exogenous GM-CSF markedly reduces G-CSF and IL-8 concentrations and increases M-CSF levels. The increase of IL-3 and the decrease of IL-5 levels were similarly observed in patients treated with G-CSF/Epo or GM-CSF/Epo.

Altogether, these results indicate that exogenous HGFs modulate endogenous cytokine levels; consideration of these aspects may contribute to optimize HGF treatment protocols in the clinical SCT setting.

We also evaluated the relationship between these phenomena and Lf release: (1) in all three groups the Lf concentration is strictly and directly correlated with the neutrophil response with respect to time-response patterns and plasma levels. (2) In patients subjected to SCT alone, the G-CSF decrease after the G-CSF peak coincides with initiation of the Lf response; the inverse correlation between these two parameters is highly significant (data not shown). Altogether, these temporal correlations after SCT provide circumstantial evidence that, after the G-CSF peak, the generated granulocytes release Lf, which could negatively feedback on the release of G-CSF, thus in line with the experimental model proposed by Broxmeyer.13 

We thank M. Fontana and C. Mastropietro for typing the manuscript, D. Marinelli for editorial assistance, and M. Teragnoli for graphics. This study was supported in part by CNR (ACRO Project, No. 95.00525.39, No. 95.00545.39), Rome and AIRC, Milan, Italy.

1
Kessinger
A
Armitage
JO
The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies.
Blood
77
1991
211
2
Brandt
SJ
Peters
WP
Atwater
SK
Kurtzberg
J
Borowitz
MJ
Jones
RB
Shpall
EJ
Bast
RC Jr
Gilbert
CJ
Oette
DH
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
N Engl J Med
318
1988
869
3
Nemunaitis
J
Rabinowe
SN
Singer
JW
Bierman
PJ
Vose
JM
Freedman
AS
Onetto
N
Gillis
S
Oette
D
Gold
M
Buckner
CD
Hansen
JA
Ritz
J
Appelbaum
FR
Armitage
JO
Nadler
LM
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
N Engl J Med
324
1991
1773
4
Sallerfors
B
Olofsson
T
Lenhoff
S
Granulocyte-macrophage colony-stimulating factor (GM-CSF ) and granulocyte-stimulating factor (G-CSF ) in serum in bone marrow transplanted patients.
Bone Marrow Transplant
8
1991
191
5
Rabinowitz
J
Petros
WP
Stuart
AR
Peters
WP
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
Blood
81
1993
2452
6
Cairo
MS
Suen
Y
Sender
L
Gillan
ER
Ho
W
Plunkett
JM
Van de Ven
C
Circulating granulocyte colony-stimulating factor (G-CSF ) levels after allogeneic and autologous bone marrow transplantation: Endogenous G-CSF production correlates with myeloid engraftment.
Blood
79
1992
1869
7
Haas
R
Gericke
G
Witt
B
Cayeux
S
Hunstein
W
Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation.
Exp Hematol
21
1993
109
8
Baiocchi
G
Scambia
G
Benedetti
P
Menichella
G
Testa
U
Pierelli
L
Martucci
R
Foddai
ML
Bizzi
B
Mancuso
S
Peschle
C
Autologous stem cell transplantation: Sequential production of hematopoietic cytokines underlying granulocyte recovery.
Cancer Res
53
1993
1297
9
Testa
U
Martucci
R
Rutella
S
Scambia
G
Sica
S
Benedetti
Panici P
Pierelli
L
Menichella
G
Leone
G
Mancuso
S
Peschle
C
Autologous stem cell transplantation: Release of early- and late-acting growth factors relates with hemopoietic ablation and recovery.
Blood
84
1994
3532
10
Brugger
W
Heimfeld
S
Berenson
RJ
Mertelsmann
R
Kanz
L
Reconstitution of hematopoiesis after high-dose chemotherapy by autologous cells generated ex vivo.
N Engl J Med
333
1995
283
11
Watts
MJ
Jones
HM
Sullivan
AM
Langabeer
SE
Jamieson
E
Fielding
A
Williams
C
Berenson
RJ
Goldstone
AH
Linch
DC
Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation.
Br J Haematol
919
1995
767
12
Sica S, Testa U, Rutella S, Martucci R, Chiusolo P, Etuk B, Di Mario A, Leone G, Peschle C: Endogenous cytokine production after immunoselected CD34+ peripheral blood progenitor cell transplant: Comparison with unfractionated progenitor transplant. Br J Haematol 1996 (in press)
13
Broxmeyer
HE
Smithyman
A
Eger
RR
Identification of lactoferrin as granulocyte-derived inhibitor of colony-stimulating activity production.
J Exp Med
148
1978
1052
Sign in via your Institution